Outcome of Core Binding Factor Acute Myeloid Leukemia in Children: A Single-Center Experience. Issue 6 (August 2020)

• Record Type: Journal Article
• Authors: Mansoor, Neelum; Jabbar, Naeem; Arshad, Uzma; Maqsood, Sidra; Habib, Muhammad A.; Raza, Muhammad R.
• Is Part Of: Journal of pediatric hematology/oncology. Volume 42:Issue 6(2020)
• Publication Date: 2020-08
• Subjects: acute myeloid leukemia -- core binding factor -- survival outcome; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000001853
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : Childhood acute myeloid leukemia (AML) harboring core binding factor (CBF)–associated translocations are considered as a favorable cytogenetic subgroup. The 2 major subtypes of CBF-AML include t(8;21) and inversion of chromosome 16, accounting for ∼25% of patients. Because of expensive and toxic treatment, which may require hospitalization during the entire course of induction chemotherapy, most of the centers in Pakistan neither workup for this low-risk entity nor offer curative treatment. Therefore, we adopted an approach of screening AML cases for the presence of CBF with the rationale of offering curative treatment to this subgroup. Data of 244 cases were reviewed, and translocations were found in 72 (34%) patients among them, 59 (82%) had t(8;21) and 13 (18%) showed inversion of chromosome 16. The event-free survival with and without abandonment was 36% and 40%, respectively. Among 44 patients who completed treatment, 26 (59%) are leukemia-free, while 18 (41%) relapsed. None of the relapsed patients received salvage chemotherapy or hematopoietic stem cell transplant. Treatment-related mortality and abandonment was found in 24% and 10% of patients, respectively. The frequency of CBF-AML is higher in our study; however, poor outcome demands holistic measures in supportive care to improve the survival.